Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -23.40% is 49% above its 5-year average of -45.48%, near the high end of its 5-year range (-503.28%–75.80%).
32.90% below its 12-month average of -17.61%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -15.50%.
NET PROFIT MARGIN
-23.40%
NET PROFIT MARGIN AVG TTM
-17.61%
NET PROFIT MARGIN AVG 3Y
-30.35%
NET PROFIT MARGIN AVG 5Y
-45.48%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-32.90%
CURRENT VS 3Y AVG
+22.91%
CURRENT VS 5Y AVG
+48.54%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-6585.71%
vs the sector median at left
GeneDx Holdings Corp.
Market Cap
$2.13B
Net Profit Margin
-23.40%
TTM Avg
-17.61%
3Y Avg
-30.35%
5Y Avg
-45.48%
Market Cap
$2.11B
Net Profit Margin
7.13%
TTM Avg
6.55%
3Y Avg
5.96%
5Y Avg
5.57%
Market Cap
$2.11B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.11B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-1032.53%
5Y Avg
-880.74%
Market Cap
$2.17B
Net Profit Margin
-37.07%
TTM Avg
-63.15%
3Y Avg
-35.64%
5Y Avg
-15.45%
Market Cap
$2.08B
Net Profit Margin
-36.51%
TTM Avg
-21.30%
3Y Avg
-316.14%
5Y Avg
-299.31%
Market Cap
$2.06B
Net Profit Margin
-544.06%
TTM Avg
-44935.33%
3Y Avg
-43227.84%
5Y Avg
-31022.63%
Market Cap
$2.06B
Net Profit Margin
-268385.71%
TTM Avg
-9751.05%
3Y Avg
-6580.61%
5Y Avg
-4774.06%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GeneDx Holdings Corp. (WGS) | $2.13B | -23.40% | -17.61% | -30.35% | -45.48% |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 7.13% | 6.55% | 5.96% | 5.57% |
| Vera Therapeutics, Inc. (VERA)vs › | $2.11B | 0.00% | 0.00% | 0.00% | 0.00% |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | 0.00% | 0.00% | -1032.53% | -880.74% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.17B | -37.07% | -63.15% | -35.64% | -15.45% |
| Pharvaris N.V. (PHVS)vs › | $2.17B | 0.00% | 0.00% | 0.00% | 0.00% |
| Alvotech (ALVO)vs › | $2.08B | -36.51% | -21.30% | -316.14% | -299.31% |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | -544.06% | -44935.33% | -43227.84% | -31022.63% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | -268385.71% | -9751.05% | -6580.61% | -4774.06% |
| Vericel Corporation (VCEL)vs › | $2.05B | 7.91% | 5.18% | -0.36% | -0.65% |
Operating Margin
-2.8%
Net Profit Margin
-23.4%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -15.50% |
| 2026-03-31 | -61.92% |
| 2025-12-31 | -14.60% |
| 2025-09-30 | -6.54% |
| 2025-06-30 | 10.53% |
| 2025-03-31 | -7.49% |
| 2024-12-31 | 5.69% |
| 2024-09-30 | -10.81% |
| 2024-06-30 | -41.37% |
| 2024-03-31 | -32.42% |
| 2023-12-31 | -44.89% |
| 2023-09-30 | -79.33% |
| 2023-06-30 | -95.92% |
| 2023-03-31 | -141.38% |
| 2022-12-31 | -503.28% |
| 2022-09-30 | -93.21% |
| 2022-06-30 | -237.06% |
| 2022-03-31 | -142.56% |
| 2021-12-31 | -69.94% |
| 2021-09-30 | 75.80% |
| 2021-06-30 | -98.18% |
| 2021-03-31 | -298.71% |
| 2020-12-31 | -196.51% |
| 2020-09-30 | -146.64% |
